Effect of terguride on prolactin levels in normal, puerperal and hyperprolactinaemic women

P. L. Venturini, R. Horowski, M. Valenzano, S. Costantini, V. Fasce, F. Gorlero, E. Rainer, L. De Cecco

Research output: Contribution to journalArticlepeer-review

Abstract

Terguride, is an 8 - alpha - ergoline derived from lisuride, acts as a partial dopamine (DA) agonist. The effect and tolerance of terguride has been investigated by an acute administration of 0.2 mg p.o. to 8 normal women, 8 patients with hyperprolactinaemia and 8 women with puerperal hyperprolactinaemia. Prolactin (PRL) levels were markedly suppressed in all subjects, with no significant differences between the groups. Treatment for 5 days with terguride 0.4 mg/day or 0.8 mg/day was studied as an inhibitor of lactation. PRL levels were suppressed in a dose-related manner. No untoward side-effects were noted.

Original languageEnglish
Pages (from-to)195-197
Number of pages3
JournalEuropean Journal of Clinical Pharmacology
Volume30
Issue number2
DOIs
Publication statusPublished - Mar 1986

Keywords

  • anti-prolactin drugs
  • ergolines
  • prolactin suppression
  • puerperal lactation
  • terguride

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Effect of terguride on prolactin levels in normal, puerperal and hyperprolactinaemic women'. Together they form a unique fingerprint.

Cite this